Ascendis Pharma A/S (NASDAQ:ASND) Receives $192.07 Average Price Target from Brokerages

Ascendis Pharma A/S (NASDAQ:ASND) has been given an average recommendation of “Moderate Buy” by the fourteen analysts that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and thirteen have issued a buy recommendation on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $192.07.

ASND has been the topic of several recent analyst reports. Stifel Nicolaus boosted their price target on Ascendis Pharma A/S from $200.00 to $207.00 and gave the stock a “buy” rating in a research note on Friday, November 15th. Cantor Fitzgerald restated an “overweight” rating and set a $170.00 price objective on shares of Ascendis Pharma A/S in a research note on Friday, November 15th. Wells Fargo & Company upped their price objective on Ascendis Pharma A/S from $264.00 to $289.00 and gave the company an “overweight” rating in a research note on Tuesday, September 17th. JPMorgan Chase & Co. cut their price objective on Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating on the stock in a research note on Wednesday, October 23rd. Finally, Bank of America upped their price objective on Ascendis Pharma A/S from $175.00 to $191.00 and gave the company a “buy” rating in a research note on Monday, September 23rd.

Ascendis Pharma A/S Stock Performance

NASDAQ:ASND opened at $134.04 on Thursday. Ascendis Pharma A/S has a one year low of $111.09 and a one year high of $161.00. The business’s 50-day simple moving average is $132.77 and its 200 day simple moving average is $133.58. The stock has a market cap of $8.13 billion, a price-to-earnings ratio of -16.59 and a beta of 0.65.

Hedge Funds Weigh In On Ascendis Pharma A/S

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Wilmington Savings Fund Society FSB acquired a new position in Ascendis Pharma A/S during the 3rd quarter worth $30,000. GAMMA Investing LLC lifted its holdings in Ascendis Pharma A/S by 58.0% in the fourth quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 214 shares during the period. Signaturefd LLC lifted its holdings in Ascendis Pharma A/S by 13.2% in the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock worth $102,000 after purchasing an additional 80 shares during the period. Pursue Wealth Partners LLC acquired a new stake in Ascendis Pharma A/S in the third quarter worth about $217,000. Finally, Rhumbline Advisers lifted its holdings in Ascendis Pharma A/S by 10.3% in the second quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock worth $209,000 after purchasing an additional 143 shares during the period.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.